Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma

Molecular Cancer Research : MCR
Guus J J E HeynenPrashanth Kumar Bajpe

Abstract

Neuroblastoma cell lines can differentiate upon treatment with retinoic acid (RA), a finding that provided the basis for the clinical use of RA to treat neuroblastoma. However, resistance to RA is often observed, which limits its clinical utility. Using a gain-of-function genetic screen, we identified an unexpected link between RA signaling and mastermind-like 3 (MAML3), a known transcriptional coactivator for NOTCH. Our findings indicate that MAML3 expression leads to the loss of activation of a subset of RA target genes, which hampers RA-induced differentiation and promotes resistance to RA. The regulatory DNA elements of this subset of RA target genes show overlap in binding of MAML3 and the RA receptor, suggesting a direct role for MAML3 in the regulation of these genes. In addition, MAML3 has RA-independent functions, including the activation of IGF1R and downstream AKT signaling via upregulation of IGF2, resulting in increased proliferation. These results demonstrate an important mechanistic role for MAML3 in proliferation and RA-mediated differentiation. MAML3 coordinates transcription regulation with receptor tyrosine kinase pathway activation, shedding new light on why this gene is mutated in multiple cancers. Mol Canc...Continue Reading

References

Oct 31, 1985·The New England Journal of Medicine·R C SeegerD Hammond
Jan 25, 1996·The New England Journal of Medicine·H CaronR Versteeg
May 1, 1996·Brain Research. Molecular Brain Research·S KanazirL Rakic
Mar 4, 2000·The EMBO Journal·F RastinejadS Khorasanizadeh
Nov 17, 2005·Molecular and Cellular Biology·Mingqiang RenNicoletta Sacchi
Nov 25, 2005·The New England Journal of Medicine·Edward F AttiyehUNKNOWN Children's Oncology Group
Feb 24, 2007·The Journal of Biological Chemistry·Yongtong ZhaoVimla Band
Mar 6, 2007·Genes, Chromosomes & Cancer·Marta WinnesGöran Stenman
Jun 26, 2007·Lancet·John M MarisSusan L Cohn
Sep 21, 2007·Nature Reviews. Neuroscience·Malcolm Maden
Oct 17, 2008·Nature·Isabelle Janoueix-LeroseyOlivier Delattre
Jan 8, 2009·The Oncologist·Su Young KimLee J Helman
May 28, 2009·Nuclear Receptor Signaling·Cécile Rochette-Egly, Pierre Germain
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tao LuGeorge R Stark
Oct 21, 2009·Current Oncology Reports·Sabine Mueller, Katherine K Matthay
Mar 17, 2010·The Journal of Biological Chemistry·Baofeng JinLizi Wu
Apr 26, 2011·Methods in Molecular Biology·Irene V BijnsdorpGodefridus J Peters
Jul 7, 2012·Biochemical and Biophysical Research Communications·Jingbo QiaoDai H Chung
Jan 18, 2013·PLoS Genetics·Takashi WatanabeHiroshi Asahara
Jun 19, 2013·Molecular and Cellular Biology·Prashanth Kumar BajpeSidong Huang
May 27, 2014·Nature Genetics·Xiaoke WangAndré M Oliveira
Jan 22, 2015·Nucleic Acids Research·Matthew E RitchieGordon K Smyth

❮ Previous
Next ❯

Citations

Jan 10, 2017·Frontiers in Molecular Neuroscience·Mumtaz KasimMichael Fähling
Jan 12, 2021·Frontiers in Cell and Developmental Biology·Sabrina ZemaDiana Bellavia
Feb 13, 2021·International Journal of Molecular Sciences·Daniel PensoldGeraldine Zimmer-Bensch
May 15, 2021·Molecular Cancer Research : MCR·Nathaniel AlzofonLauren Fishbein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.